About Us

Company Description

Ophelos Therapeutics Pty Ltd is a UK corporation with offices and laboratories in the UK and Australia, led by pioneers in innovation of cell therapy product and services, supported by a seasoned pharma management team and respected scientific research team. As a result of many years of research and development, the Company’s science team has discovered a novel technology platform that has led to the development of new Adoptive T/NK cell therapies with improved therapeutic selectivity and efficacy.

0 +

Years Experienced

0 +

Papers

0 +

Potential Cancer Treatments

Despite the extensive clinical utilization and success of chemotherapy drugs, serious and life-threatening toxic effects are associated with their administration. To prevent and manage these serious problems,
premedication and post-medication must routinely be administered, which
increases the possibility of drug interactions.

This is the major reason why administration of chemotherapy drugs are
performed in a hospital environment.

Therefore, an improved chemotherapy drug formulation, which could minimise the adverse effects associated with these drugs, while retaining similar anticancer activity, would greatly benefit cancer patients and their caregivers.

Overview

Platform Overview

Glycoconjugates represent a recent trend in cancer chemotherapy that adopts the concept of selective prodrug/drug targeting of tumor cells by binding to specific transmembrane glucose transporters. Following preferential uptake of sugar conjugates into cancer cells, they are presumably subject to enzymatic cleavage by specific beta-glycosidases to liberate the free active cytotoxic aglycones that act selectively on cancer cells and spare other noncancerous ones.

NK cell Performance
In the field of biotechnology, one company stands out for its groundbreaking advancements in combating T/NK cell exhaustion in immunotherapy. Through innovative research and development efforts, Ophelos Tx has pioneered technologies aimed at enhancing the effectiveness of adoptive T/NK cell therapies. By addressing T/NK cell exhaustion, a significant barrier to sustained anti-tumor responses, Ophelos Tx approach holds promise for improving patient outcomes and expanding the applicability of immunotherapeutic treatments.
Better Targeting
Through cutting-edge research and innovative technologies, Ophelos Tx is at the forefront of developing T/NK cell receptor-based therapies that harness the power of the immune system to target specific tumor markers. Our approach involves genetically modifying natural killer (NK) isolated from the patient to express receptors that recognize and attack their cancer cells, offering a personalized and precise treatment option for patients battling various types of cancers. By identifying and utilizing peptide antigens, Ophelos Tx aims to revolutionize adoptive T cell therapies, providing hope for improved outcomes and quality of life for individuals facing cancer.
The Target
Ophelos Tx’s proprietary technology leverages specific peptide antigens to precisely target two critical components of cancer progression: senescent cells and cancer stem cells. By harnessing the power of adoptive T cell therapies, we aim to deliver a dual-action approach that not only eradicates cancer cells but also disrupts their ability to regenerate and spread. This innovative strategy holds immense potential for improving patient outcomes and overcoming challenges associated with tumor recurrence and resistance. With a commitment to cutting-edge research and development, Ophelos Tx is at the forefront of transforming cancer treatment paradigms.

Why Us

Cell Therapy Product Cancer Target (Arrow) Discovery Synthesis Preclinical Clinical

NK-OPH007 Overall (Preclinical)
NK-CSC-CRC-013 Colorectal cancer (Synthesis)
NK-HPV-CC-001 Cervical Cancer (Discovery)
HK-CSC-OC-003 Ovarian Cancer (Discovery)
HK-CSC-PR-001 Prostate Cancer (Discover

Our core technology exhibits substantial competitive advantages in immunotherapy over the use of standard cell therapy protocols.

Media

Ophelos’s groundbreaking technology offers tremendous promise to millions of patients suffering from cancer. If you would like to learn more about Ophelos, our technology platform, our research drug/cell pipeline in progress, please contact us…